Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

20092,186 citationsJournal Article

Authors

Robert J. Motzer · Texas Oncology

Thomas E. Hutson · Texas Oncology

Piotr Tomczak · Texas Oncology

M. Dror Michaelson · Texas Oncology

Ronald M. Bukowski · Texas Oncology

Stéphane Oudard · Texas Oncology

Sylvie Négrier · Texas Oncology

Abstract

Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 27, Issue 22, pp. 3584-3590

DOI: 10.1200/jco.2008.20.1293

Field-Weighted Citation Impact: 141.78